Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.
Incheon, Republic of Korea—based Samsung Bioepis has launched its trastuzumab biosimilar Ontruzant in Brazil for the treatment of patients with early and metastatic HER2-positive breast cancer and advanced gastric cancer.
The drug references Herceptin and was previously approved by the Agência Nacional de Vigilância Sanitária in May 2019. Besides Brazil, Ontruzant is currently marketed in Australia, Europe, the United States, Ukraine and Republic of Korea. It received authorizations in Europe and the United States in 2017 and 2019, respectively.
"A Step Closer"
“The launch of our first oncology treatment Ontruzant in Brazil is a step closer to realizing our mission which is to deliver high quality, proven biologic medicines to more people, said Josh Sang Hyun Lee, vice president and commercial strategy team lead, Samsung Bioepis.
Breast cancer is the most common cancer and main cause of death among women in Brazil. There are an estimated 67,000 deaths from this disease each year in Brazil and the number is growing by 2.54% each year, Samsung Bioepis said in a statement.
According to a 2019 market report by McKinsey & Company, the potential scope of Brazil’s biosimilar market ranked second in the world among emerging countries. McKinsey projected a market size of $1.9 billion by 2025 with an annual growth rate of 25% to 30%. That was larger than the projection for India ($1.4 billion; 15%-20% growth), but well short of China’s ($8.1 billion; 20%-25%).
In Brazil, biologics account for less than 5% of volume of drug sales but roughly 40% of health ministry spending on drugs, according to McKinsey. The drug approval pathway in Brazil is based on World Health Organization and European Medicines Agency guidelines.
Ontruzant is being supplied to the country’s public health system, Sistema Único de Saúde, through a partnership between Samsung Bioepis and local partners, Bionovis and Bio-Manguinhos.
Recent Developments
Samsung Bioepis was established in 2012 and is developing biosimilars in immunology, oncology, ophthalmology, and hematology. It is a joint venture between Samsung BioLogics and Biogen.
In June, the company initiated a phase 3 trial for its aflibercept biosimilar SB15, referencing Eylea. The randomized multicenter study will compare the efficacy, safety, pharmacokinetics, and immunogenicity between the biosimilar and the reference product in 446 patients with neovascular age-related macular degeneration.
The company also has a ranibizumab (SB11) ophthalmology candidate in clinical development.
Also in June, the company’s bevacizumab candidate (Aybintio), referencing Avastin, was recommended for marketing authorization by the European Medicines Agency. The drug was recommended for the same indications as the reference product, including metastatic carcinoma of the colon or rectum, metastatic breast cancer, non—small cell lung cancer, advanced or metastatic renal cell cancer, epithelial ovarian, fallopian tube and primary peritoneal cancer, and cervical cancer.
In early August, Samsung Bioepis announced it had received a prestigious Red Dot Design Award for its innovative packaging design featuring natural shapes and colors designed to inspire confidence and peace in patients and “move away from the conventional, rigid design of medicine packaging” focused only on delivery of safety information.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.